NT Pharma puts off listing, Kingstone Marble sets range
Hong Kong-based NT Pharma has delayed the launch of an initial public offering that was expected to start pre-marketing this week. The company is still working on the documentation for the deal, said a bookrunner.
Goldman Sachs and UBS were expected to start pre-marketing the $250m-$300m NT Pharma deal on Friday. "The company is still working on the numbers," said a banker close to the deal.
That means Shanghai Pharmaceutical will be able to launch its offer next week without competition from another pharmaceutical
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: email@example.com
To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: firstname.lastname@example.org or find out more online here.